Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

A prospective Study of whole genome sequencing for genomic profiling and risk determination in MDS

Rigoberto De Jesus, Samuel Urrutia, David Spencer, Eric Duncavage, Tasha Burton, Na'kie Coleman-elhasan, Sridhar Srivatsan, Molly Schroeder, Kilannin Krysiak, Geoffrey Uy, Timothy Ley, Matthew Walter, Meagan Jacoby

Blood (2025) 146 (Supplement 1): 5640.

https://doi.org/10.1182/blood-2025-5640

Published: 2025

Journal Articles

The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome

Benjamin Rolles, Jan Philipp Bewersdorf, Tariq Kewan, Ondrej Blaha, Jessica Stempel, Luca Lanino, Najla Al Ali, Amy DeZern, Mikkael Sekeres, Geoffrey Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth Griffiths, Eytan Stein, Andrew Brunner, Christine McMahon, Rory Shallis, Joshua Zeidner, Michael Savona, Namrata Chandhok, Constantine Logothetis, Aram Bidikian, Theodore Getz, Gail Roboz, Eunice Wang, Maria Amaya, Hayley Hawkins, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Talha Badar, Jaclynn Campos, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop Enjeti, Kamal Alrabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Matteo Della Porta, Rami Komrokji, Amer Zeidan, Maximilian Stahl

Blood (2025) 146 (Supplement 1): 3865.

https://doi.org/10.1182/blood-2025-3865

Published: 2025

Journal Articles

Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database

Tariq Kewan, Jan Philipp Bewersdorf, Luca Lanino, Ondrej Blaha, Jessica Stempel, Najla Al Ali, Amy DeZern, Mikkael Sekeres, Geoffrey Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth Griffiths, Eytan Stein, Andrew Brunner, Christine McMahon, Rory Shallis, Joshua Zeidner, Michael Savona, Namrata Chandhok, Constantine Logothetis, Aram Bidikian, Theodore Getz, Gail Roboz, Benjamin Rolles, Eunice Wang, Amyah Harris, Maria Amaya, Hayley Hawkins, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Talha Badar, Jaclynn Campos, Torsten Haferlach, Jaroslaw Maciejewski, Anoop Enjeti, Kamal Al-Rabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Rami Komrokji, Maximilian Stahl, Matteo Della Porta, David Sallman, Amer Zeidan

Blood (2025) 146 (Supplement 1): 3863.

https://doi.org/10.1182/blood-2025-3863

Published: 2025

Journal Articles

An open-label phase I study of JAK inhibitor ruxolitinib with and without CTLA-4 ig abatacept for the prophylaxis of graft-versus-host ddsease and cytokine release syndrome after T-cell replete haploidentical peripheral blood hematopoietic cell transplantation

Ramzi Abboud, Feng Gao, Maggie Nash, Jeffrey King, Samantha Bauer, Camille Abboud, Zachary Crees, Meagan Jacoby, Iskra Pusic, Mark Schroeder, Samuel Urrutia, Geoffrey Uy, John DiPersio

Blood (2025) 146 (Supplement 1): 2459.

https://doi.org/10.1182/blood-2025-2459

Published: 2025

Journal Articles

Characteristics, survival, and causes of death in patients with APL from Chile

Andres Ramirez, Macarena Roa, Carolina Infante O, Paulina Cornejo V, Karla Mellado C, Andrea Encina R, Camila Peña, Maria Undurraga, Diana Patricia Gonzalez Hermosa, Jennifer Lewis, Leticia Campoverde, Cristobal Frutos Ortiz, Luis Malpica, Samuel Urrutia

Blood (2025) 146 (Supplement 1): 6901.

https://doi.org/10.1182/blood-2025-6901

Published: 2025

Journal Articles

Outcomes of patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) treated with hypomethylating agents (HMA) + venetoclax (VEN) – a large analysis from the international consortium for MDS (icMDS) validate database

Jan Philipp Bewersdorf, Tariq Kewan, Luca Lanino, Wei Wei, Najla Al Ali, Amy DeZern, Mikkael Sekeres, Geoffrey Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth Griffiths, Eytan Stein, Andrew Brunner, Christine McMahon, Rory Shallis, Joshua Zeidner, Michael Savona, Hayley Hawkins, Namrata Chandhok, Constantine Logothetis, Aram Bidikian, Theodore Getz, Gail Roboz, Benjamin Rolles, Eunice Wang, Amyah Harris, Maria Amaya, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Jaclynn Campos, Talha Badar, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop Enjeti, Kamal Alrabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Max Stahl, Matteo Della Porta, Rami Komrokji, Amer Zeidan

Blood (2025) 146 (Supplement 1): 606.

https://doi.org/10.1182/blood-2025-606

Published: 2025

Journal Articles

Outcomes and cause-specific mortality of AML in adults from Chile

Macarena Roa, Andres Ramirez, Carolina Infante O, Paulina Cornejo V, Karla Mellado C, Andrea Encina R, Camila Peña, Maria Undurraga, Diana Patricia Gonzalez Hermosa, Jennifer Lewis, Leticia Campoverde, Luis Malpica, Cristobal Frutos Ortiz, Samuel Urrutia

Blood (2025) 146 (Supplement 1): 1604.

https://doi.org/10.1182/blood-2025-1604

Published: 2025

Journal Articles

Impact of pre-allogeneic stem cell transplantation (SCT) disease characteristics, therapy, and response on post-SCT outcomes in higher risk myelodysplastic syndromes

Blood (2025) 146 (Supplement 1): 6075.

https://doi.org/10.1182/blood-2025-6075

Published: 2025

Journal Articles

A clinical guide to TP53 mutations in myeloid neoplasms

Samuel Urrutia, Terrence N. Wong, Daniel C. Link

Blood (2025) 146 (18): 2157–2167.

https://doi.org/10.1182/blood.2025029691

Published: 2025

Journal Articles

Causes of Death in Patients with Myelodysplastic Syndrome and Spliceosome Mutations

Arjun S. Peddireddy, Panayiotis Kontoyiannis, Koji Sasaki, Kelly S. Chien, Jayastu Senapati, Guillermo Montalban-Bravo, Courtney D. DiNardo, Gautam Borthakur, Rashmi Kanagal-Shamanna, Carlos E. Bueso-Ramos, Sherry Pierce, Hagop M. Kantarjian, Guillermo Garcia-Manero, Samuel Urrutia

Blood (2024) 144 (Supplement 1): 6704.

https://doi.org/10.1182/blood-2024-202540

Published: 2024

Journal Articles

Survival Benefits of Complete Cytogenetic Response in Patients with Newly Diagnosed Myelodysplastic Syndrome

Roberta Santos Azevedo, Hagop M. Kantarjian, Elias Jabbour, Rashmi Kanagal-Shamanna, Kelly S. Chien, Danielle Hammond, Samuel Urrutia, Carlos E. Bueso-Ramos, Keyur P. Patel, Guillermo Montalban-Bravo, Nicholas J. Short, Naval Daver, Gautam Borthakur, Tapan M. Kadia, William G. Wierda, Guillermo Garcia-Manero, Koji Sasaki

Blood (2024) 144 (Supplement 1): 6727.

https://doi.org/10.1182/blood-2024-201864

Published: 2024

Journal Articles

Impact of Flow Cytometry-Based Measurable Residual Disease Clearance Kinetics in Patients with Acute Myeloid Leukemia Undergoing Intensive Chemotherapy

Wei-Ying Jen, Koji Sasaki, Farhad Ravandi, Tapan M. Kadia, Sa A. Wang, Wei Wang, Sanam Loghavi, Naval Daver, Courtney D. DiNardo, Ghayas C. Issa, Hussein A. Abbas, Cedric Nasnas, Alex Bataller, Samuel Urrutia, Sherry Pierce, Hagop M. Kantarjian, Nicholas J. Short

Blood (2024) 144 (Supplement 1): 1572.

https://doi.org/10.1182/blood-2024-212036

Published: 2024

Journal Articles

Oral Decitabine/Cedazuridine in Patients with MDS and TP53 Mutations: A Propensity Score Matching Analysis from the Phase II and III Trials

Samuel Urrutia, Koji Sasaki, Alex Bataller, Hagop M. Kantarjian, Guillermo Montalban-Bravo, James McCloskey, Elizabeth A. Griffiths, Karen Yee, Amer M. Zeidan, Michael R. Savona, Aram Oganesian, Yuri Sano, Harold N. Keer, Guillermo Garcia-Manero

Blood (2024) 144 (Supplement 1): 661.

https://doi.org/10.1182/blood-2024-193274

Published: 2024

Journal Articles

Characteristics of Myelodysplastic Syndromes with Idiopathic Pulmonary Fibrosis

Ines Zugasti, Samuel Urrutia, Eduardo Edelman Saul, Georgina Daher-Reyes, Mohammed Asim Amjad, Jia Wu, Koji Sasaki, Ajay Sheshadri, Guillermo Garcia-Manero

Blood (2024) 144 (Supplement 1): 4587.

https://doi.org/10.1182/blood-2024-207293

Published: 2024

Journal Articles

Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Treated with Hypomethylating Agent-Based Therapy: A Multicenter Analysis

Blood (2024) 144 (Supplement 1): 4584.

https://doi.org/10.1182/blood-2024-210646

Published: 2024

Journal Articles

Characteristics and Survival Outcome of Patients with Isolated 11q Deletion Myelodysplastic Syndromes

Blood (2024) 144 (Supplement 1): 6746.

https://doi.org/10.1182/blood-2024-208444

Published: 2024

Journal Articles

Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia

Blood (2023) 142 (19): 1647–1657.

https://doi.org/10.1182/blood.2023020649

Published: 2023

Includes: Supplemental data

Journal Articles

A Phase 2 Study of Canakinumab in Patients with Lower-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Juan Jose Rodriguez Sevilla, Vera Adema, Kelly S. Chien, Irene Ganan-Gomez, Guillermo Montalban-Bravo, Samuel Urrutia, Joby Joseph, Hui Yang, Gautam Borthakur, Nicholas J. Short, Ghayas C. Issa, Tapan M. Kadia, Koichi Takahashi, Danielle E. Hammond, Guillermo Garcia-Manero

Blood (2023) 142 (Supplement 1): 1866.

https://doi.org/10.1182/blood-2023-185259

Published: 2023

Journal Articles

Update of a Phase II Trial of Guadecitabine in Higher-Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Under the International Working Group 2023 Criteria

Samuel Urrutia, Kelly S. Chien, Ziyi Li, Gautam Borthakur, Yesid Alvarado Valero, Tapan M. Kadia, Steven M. Kornblau, Naval Daver, Farhad Ravandi, Prithviraj Bose, Musa Yilmaz, Maro Ohanian, Rashmi Kanagal-Shamanna, Carlos E. Bueso-Ramos, Hagop M. Kantarjian, Guillermo Garcia-Manero

Blood (2023) 142 (Supplement 1): 1877.

https://doi.org/10.1182/blood-2023-184690

Published: 2023

Journal Articles

Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Hypomethylating Agent-Treated Patients with Myelodysplastic Syndromes

Blood (2023) 142 (Supplement 1): 1857.

https://doi.org/10.1182/blood-2023-189557

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

A prospective Study of whole genome sequencing for genomic profiling and risk determination in MDS

The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome

Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database

An open-label phase I study of JAK inhibitor ruxolitinib with and without CTLA-4 ig abatacept for the prophylaxis of graft-versus-host ddsease and cytokine release syndrome after T-cell replete haploidentical peripheral blood hematopoietic cell transplantation

Characteristics, survival, and causes of death in patients with APL from Chile

Outcomes of patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) treated with hypomethylating agents (HMA) + venetoclax (VEN) – a large analysis from the international consortium for MDS (icMDS) validate database

Outcomes and cause-specific mortality of AML in adults from Chile

Impact of pre-allogeneic stem cell transplantation (SCT) disease characteristics, therapy, and response on post-SCT outcomes in higher risk myelodysplastic syndromes

A clinical guide to TP53 mutations in myeloid neoplasms

Causes of Death in Patients with Myelodysplastic Syndrome and Spliceosome Mutations

Survival Benefits of Complete Cytogenetic Response in Patients with Newly Diagnosed Myelodysplastic Syndrome

Impact of Flow Cytometry-Based Measurable Residual Disease Clearance Kinetics in Patients with Acute Myeloid Leukemia Undergoing Intensive Chemotherapy

Oral Decitabine/Cedazuridine in Patients with MDS and TP53 Mutations: A Propensity Score Matching Analysis from the Phase II and III Trials

Characteristics of Myelodysplastic Syndromes with Idiopathic Pulmonary Fibrosis

Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Treated with Hypomethylating Agent-Based Therapy: A Multicenter Analysis

Characteristics and Survival Outcome of Patients with Isolated 11q Deletion Myelodysplastic Syndromes

Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia

A Phase 2 Study of Canakinumab in Patients with Lower-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Update of a Phase II Trial of Guadecitabine in Higher-Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Under the International Working Group 2023 Criteria

Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Hypomethylating Agent-Treated Patients with Myelodysplastic Syndromes

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only